• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

June 24, 2019
Company Drug/Device Medical Condition Status
Cellular Biomedicine Group Inc. anti-CD20 CAR-T diffuse large B-cell lymphoma (DLBCL) Phase I trial initiated enrolling 12 subjects in China
Boehringer Ingelheim
OSE Immunotherapeutics SA
SIRPα antagonist monoclonal antibody BI 765063 (formerly OSE-172) advanced solid tumors Phase I trial initiated
Rocket Pharmaceuticals, Inc. RP-A501 Danon disease Phase I trial initiated enrolling 12-24 pediatric and young adult male subjects
BioNTech SE
Genmab A/S
DuoBody-PD-L1x4-1BB metastatic or unresectable malignant solid tumors Phase I/IIa trial initiated
Reistone Biopharma Company SHR0302 Ulcerative Colitis Phase II trial initiated
Reistone Biopharma Company SHR0302 Crohn's disease Phase II trial initiated
Zydus Cadila Saroglitazar Magnesium Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH) Phase II trial initiated enrolling 104 subjects at 20 sites across the U.S.
InflaRx N.V. IFX-1 Pyoderma Gangraenosum (PG) Phase IIa trial initiated enrolling 12 subjects with moderate to severe PG at three sites in Canada
Corvidia Therapeutics Inc. Ziltivekimab (previously known as COR-001) advanced chronic kidney disease (CKD) Phase IIb trial initiated enrolling 240 subjects at 50 sites across the U.S.
Arena Pharmaceuticals, Inc. etrasimod 2 mg ulcerative colitis (UC) Phase III trial initiated enrolling subjects with moderately to severely active UC
OxThera AB Oxabact Primary Hyperoxaluria Phase III trial initiated enrolling 22 subjects at 10 sites across Europe and the U.S.
Torque TRQ-1501 relapsed or refractory solid tumors and lymphomas that express any of five tumor-associated antigens (PRAME, WT-1, SSX2, Survivin and NY-ESO-1) Fast Track designation granted by the FDA
Bio-Techne ExoDx Prostate IntelliScore (EPI) test prostate cancer Breakthrough Device designation granted by the FDA
Camurus CAM2029 acromegaly IND approval granted by the FDA
Triumvira Immunologics, Inc. TAC01-CD19 CD19-postive B-cell malignancies IND approval granted by the FDA
Amgen
Allergan plc
KAJINTI (trastuzumab-anns) HER2-overexpressing adjuvant and metastatic breast cancer Approval granted by the FDA
Amgen
Allergan plc
KAJINTI (trastuzumab-anns) HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma Approval granted by the FDA
Novo Nordisk Victoza (liraglutide) Type 2 diabetes in children and adolescents aged 10-17 years Approval granted by the FDA
Kowa Pharmaceuticals America, Inc. LIVALO (pitavastatin) heterozygous familial hypercholesterolemia (HeFH) in subjects eight years and older Approval granted by the FDA

 

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing